Taiwan Advance Bio-Pharmaceutical (ROCO:4186) ROIC %: 9.80% (As of Dec. 2025)


ROCO:4186 Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
57 GF Score
Price NT$10.10
GF Value NT$17.88
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Taiwan Advance Bio-Pharmaceutical ROIC %?

Taiwan Advance Bio-Pharmaceutical ROCO:4186 -0.49% 57 ROIC % is 9.80% as of Dec. 2025. GuruFocus rates ROCO:4186 with a GF Score™ of 57/100 and a GF Value™ of NT$17.88 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Taiwan Advance Bio-Pharmaceutical's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was 9.80%.

As of today (2026-07-05), Taiwan Advance Bio-Pharmaceutical's WACC % is 2.81%. Taiwan Advance Bio-Pharmaceutical's ROIC % is 5.44% (calculated using TTM income statement data). Taiwan Advance Bio-Pharmaceutical generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Taiwan Advance Bio-Pharmaceutical  (ROCO:4186) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Taiwan Advance Bio-Pharmaceutical's WACC % is 2.81%. Taiwan Advance Bio-Pharmaceutical's ROIC % is 5.44% (calculated using TTM income statement data). Taiwan Advance Bio-Pharmaceutical generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Taiwan Advance Bio-Pharmaceutical ROIC % Related Terms


Taiwan Advance Bio-Pharmaceutical ROIC % Historical Data

* Premium members only.

The historical data trend for Taiwan Advance Bio-Pharmaceutical's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical ROIC % Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.88 1.10 0.57 6.36 5.45

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.52 -0.35 13.45 0.87 9.80

ROCO:4186 vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Advance Bio-Pharmaceutical ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's ROIC % distribution charts can be found below:

* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's ROIC % falls into.


ROCO:4186
57GF Score
Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Advance Bio-Pharmaceutical ROIC % Calculation

Taiwan Advance Bio-Pharmaceutical's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=37.389 * ( 1 - 0% )/( (655.402 + 716.529)/ 2 )
=37.389/685.9655
=5.45 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=676.424 - 31.457 - ( 106.324 - max(0, 238.88 - 228.445+106.324))
=655.402

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=746.739 - 35.678 - ( 140.738 - max(0, 272.228 - 266.76+140.738))
=716.529

Taiwan Advance Bio-Pharmaceutical's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=68.892 * ( 1 - 0% )/( (690.012 + 716.529)/ 2 )
=68.892/703.2705
=9.80 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=692.33 - 29.604 - ( 113.602 - max(0, 264.784 - 237.498+113.602))
=690.012

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=746.739 - 35.678 - ( 140.738 - max(0, 272.228 - 266.76+140.738))
=716.529

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 9.80% mean?
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a ROIC % of 9.80% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors.
Is Taiwan Advance Bio-Pharmaceutical's ROIC % too high?
Taiwan Advance Bio-Pharmaceutical's current ROIC % is 9.80%. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's ROIC % compare to VRTX and REGN?
Taiwan Advance Bio-Pharmaceutical's ROIC % of 9.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. Taiwan Advance Bio-Pharmaceutical's current ROIC % is 9.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.88, compared to a current price of NT$10.10 — trading 43.5% below its estimated fair value. The current ROIC % is 9.80%. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current ROIC % is 9.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued. The current stock price of NT$10.10 is trading 43.5% below its estimated GF Value™ of NT$17.88. GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:4186:

  • ROIC %: 9.80%
  • GF Value™: NT$17.88 vs. price of NT$10.10 (43.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Taiwan Advance Bio-Pharmaceutical Business Description

Address No. 363, Section 2, Fuxing South Road, 5th Floor, Daan District, New Taipei City, TWN, 22180
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
57GF Score

Get the complete analysis for ROCO:4186

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.10
Price
NT$17.88
GF Value